Julie Lellouche, Author at Labiotech.eu

About

Blogger for Labiotech.eu. Entrepreneurial Student at SupBiotech, Paris Higher Biotechnology Institute.

Articles by Julie Lellouche

News and Trends 22 Oct 2014

New Treatment against critic Leukemia Approved In Europe

Janssen’s Imbruvica (ibrutinib), the once-daily oral Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Europe as a treatment for two blood cancers. The drug has been ratified by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia. The therapy functions block BTK, a protein that […]

October 22, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

10486567 10152342154846513 5707030158597204448 o

News and Trends 18 Oct 2014

One Week European Biotech Industry Celebration

The European Biotech Week was celebrated for the second time at the beggining of October. It was an important event to discuss and develop biotechnology in Europe. The European Biotech Week was organized by EuropaBio, european organization for Biotech companies. It was also an opportunity to bring together biotech associations because they are key in helping to […]

October 18, 2014 - 1 minutemin - By Julie Lellouche

News and Trends 16 Oct 2014

A Smart Collaboration to Diagnostic and Fight Cancer

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris. Under this agreement, New Oncology (Cologne-based German Biotech company) will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both […]

October 16, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

New Peptide Technology Against Cancer bags 25 Million Euros

Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it had secured an equity financing of €25 million for the clinical development of therapeutic bicycle drug candidates in oncology. Bicycle has used its proprietary bicyclic peptide technology that enables to discover a new class of drug candidates, which have similar selectivity […]

October 15, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 15 Oct 2014

Recently Launched Company Rigontec already Raised 9,45M Euros against Cancer

Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announced the first closing of its Series A financing round, raising €9.45 million. Rigontec was launched in January 2014 as a spin-out of the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Germany. The Company’s […]

October 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 13 Oct 2014

Future Organ-on-a-chip Global Leader MIMETAS raised 4 Million euros

Dutch biotech MIMETAS B.V. announces that it has raised 4 Million euros ($5.2M) to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners, to fund development and sales of MIMETAS’ unique 3D disease- […]

October 13, 2014 - 3 minutesmins - By Julie Lellouche

News and Trends 11 Oct 2014

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production […]

October 11, 2014 - 3 minutesmins - By Julie Lellouche

Oral Insulin All Mouth or an Injection of Hope for Type 1 Diabetes medium vga

News and Trends 8 Oct 2014

Once a Week Insulin Shot : Novo Nordisk’s new Idea

Denmark’s Novo Nordisk, the world’s largest insulin seller, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world’s first once-weekly insulin injection. Almost 592 million people are expected to live with diabetes by 2035, up 55 percent from last year’s level, according to the International Diabetes […]

October 8, 2014 - 2 minutesmins - By Julie Lellouche

More News! 6 Oct 2014

Flying to New York Thanks to Cooking Oils Recycled From Restaurants

Finnair, a pioneer in sustainable flying and the first airline listed in the Leadership Index of the worldwide Carbon Disclosure Project, operated its flight from Helsinki to New York on 23 September with an Airbus A330 using environmentally sustainable biofuel, coinciding with the UN Climate Summit taking place in New York on the same day. […]

October 6, 2014 - 2 minutesmins - By Julie Lellouche

LoneStar Heart Hydrogel advanced heart attacks

News and Trends 4 Oct 2014

A Hydrogel to treat Advanced Heart Failure in Europe

LoneStar Heart, Inc. announced that it received the CE Mark (European Conformity) for its Algisyl-LVR® hydrogel implant,a product for the treatment of advanced heart failure (HF). The CE Mark indicates a product’s compliance with European Union legislation and that it can be sold throughout the European Economic Area. Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is […]

October 4, 2014 - 2 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us